GK/GK3P Antibody

What is the GK3P protein and why is it significant in cancer research?

GK3P (glycerol kinase 3 pseudogene) functions as a key enzyme in the regulation of glycerol uptake and metabolism . Despite its classification as a pseudogene, research has established that GK3P is expressed in various cell types and has been implicated as a potential oncogene in cancer development and progression . Its significance stems from observations that its overexpression correlates with various types of cancer, suggesting its role as a promising target for therapeutic interventions . Understanding GK3P's biological function provides insight into metabolic pathways that cancer cells may exploit, particularly concerning glycerol metabolism which can support cancer cell proliferation through lipid synthesis pathways and energy production.

What are the recommended applications for GK3P Antibody (PACO13463)?

The GK3P Antibody (PACO13463) has been validated for multiple experimental applications, with primary testing in ELISA, Western blotting (WB), and immunohistochemistry (IHC) . For Western blot applications, this antibody effectively detects GK3P protein in cell and tissue lysates, allowing researchers to quantify expression levels across different experimental conditions. In immunohistochemistry, the antibody enables visualization of GK3P protein localization within tissue sections, providing spatial context for expression patterns. ELISA applications permit quantitative detection of the target protein in solution. When designing experiments, researchers should implement appropriate positive and negative controls to validate antibody specificity, particularly when studying novel cell lines or tissue types beyond the validated human, mouse, and rat species reactivity .

What is the difference between GK and GK3P antibodies?

GK antibodies target glycerol kinase, an enzyme that catalyzes the phosphorylation of glycerol to glycerol-3-phosphate—a critical step in glycerol metabolism . In contrast, GK3P antibodies specifically recognize the glycerol kinase 3 pseudogene product . While both proteins share sequence similarity, they represent distinct genetic entities with potentially different biological functions. GK3P is classified as a pseudogene derivative of the functional glycerol kinase family . When selecting between these antibodies, researchers must carefully consider their experimental objectives—GK antibodies are appropriate for studying canonical glycerol metabolism, while GK3P antibodies are essential for investigating the specific roles of this pseudogene product in pathological conditions such as cancer development . Cross-reactivity between these related proteins should be evaluated through appropriate controls when designing experiments.

What species reactivity does the GK3P Antibody (PACO13463) demonstrate?

The GK3P Antibody (PACO13463) has been validated for reactivity with human, mouse, and rat species . This cross-species reactivity is particularly valuable for researchers conducting comparative studies across different model systems. The antibody was developed using human GK3P as the immunogen, which explains its strong reactivity with human samples . When working with species not explicitly listed in the validation data, researchers should perform preliminary experiments to confirm antibody binding specificity. This typically involves positive and negative control samples and may include blocking peptide competition assays to verify specific epitope recognition. The cross-species reactivity makes this antibody suitable for translational research, allowing findings from rodent models to be potentially correlated with human disease conditions.

How can computational models aid in designing antibodies with improved specificity for GK3P?

Recent advancements in computational modeling offer significant potential for enhancing GK3P antibody specificity. Researchers can employ biophysics-informed models that incorporate multiple binding modes to design antibodies with customized specificity profiles . This approach requires integration of phage display experimental data with high-throughput sequencing and machine learning techniques. The computational model associates each potential ligand with a distinct binding mode, enabling prediction of antibody variants with either specific high affinity for GK3P or cross-specificity for multiple targets if desired . The process involves:

• Conducting phage display experiments against GK3P and structurally similar proteins

• Building a computational model expressing selection probability in terms of binding modes

• Using shallow dense neural networks to parameterize energy functions for each binding mode

• Optimizing sequences to minimize energy functions for desired targets while maximizing them for undesired targets

This approach is particularly valuable when GK3P needs to be distinguished from closely related proteins with high sequence homology, allowing researchers to design antibodies that specifically recognize unique epitopes .

What are the key considerations when using GK3P antibodies to evaluate tumor samples across different cancer types?

When employing GK3P antibodies for tumor sample evaluation across cancer types, researchers must address several critical factors to ensure reliable and interpretable results:

Since GK3P overexpression has been linked to various cancer types , establishing proper controls and standardized evaluation protocols is essential for meaningful cross-cancer comparisons. Additionally, researchers should consider the subcellular localization of GK3P, as changes in localization patterns may provide insights into protein function in different tumor contexts.

How does the binding specificity of GK3P antibodies compare to other glycerol kinase family member antibodies?

The binding specificity of GK3P antibodies requires careful consideration due to potential cross-reactivity with related glycerol kinase family members. GK3P shares sequence similarity with other glycerol kinase variants, necessitating thorough validation to ensure target specificity . When comparing antibody specificity:

• Epitope mapping reveals that GK3P antibodies target regions with sufficient sequence divergence from other family members

• Western blot analysis should demonstrate bands at the expected molecular weight (approximately 61 kDa for GK3P) without significant cross-reactive bands

• Immunoprecipitation followed by mass spectrometry can confirm the precise identity of captured proteins

• Knockdown/knockout validation experiments provide definitive evidence of specificity

Researchers should be particularly vigilant about potential cross-reactivity when studying tissues that express multiple glycerol kinase family members. Pre-absorption with recombinant proteins can be employed to confirm specificity when cross-reactivity is suspected. The choice between polyclonal antibodies (like PACO13463) and monoclonal alternatives should be guided by the experimental requirements for specificity versus epitope recognition breadth .

What are the optimal conditions for using GK3P Antibody (PACO13463) in Western blotting procedures?

For optimal Western blotting with GK3P Antibody (PACO13463), researchers should implement the following protocol:

• Sample preparation:

  • Lyse cells/tissues in RIPA buffer supplemented with protease inhibitors

  • Determine protein concentration using Bradford or BCA assay

  • Load 20-50 μg of total protein per lane

• Gel electrophoresis and transfer:

  • Separate proteins on 10-12% SDS-PAGE

  • Transfer to PVDF membrane (preferable over nitrocellulose for this application)

  • Verify transfer efficiency with reversible protein stain

• Antibody incubation:

  • Block membrane with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute primary antibody (PACO13463) at 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash 3x with TBST, 5 minutes each

  • Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000) for 1 hour at room temperature

  • Wash 4x with TBST, 5 minutes each

• Detection:

  • Develop using enhanced chemiluminescence substrate

  • Expected band size: approximately 61 kDa

This protocol has been optimized based on the antibody's properties as a rabbit polyclonal IgG . For challenging samples with low target expression, increasing the primary antibody concentration and extending incubation time may improve signal detection. Always include positive control samples with known GK3P expression to validate experimental results.

How should researchers troubleshoot non-specific binding when using GK3P antibodies in immunohistochemistry?

When encountering non-specific binding with GK3P antibodies in immunohistochemistry, researchers should systematically address potential causes:

Additionally, comparing staining patterns with RNA expression data (in situ hybridization or RNA-seq) can help validate the specificity of antibody binding . For GK3P antibodies specifically, including tissues known to lack GK3P expression serves as an effective negative control. The polyclonal nature of the PACO13463 antibody means it recognizes multiple epitopes on GK3P, which might increase sensitivity but potentially raises cross-reactivity concerns .

What strategies can be employed to verify GK3P antibody specificity in new experimental systems?

Rigorous verification of GK3P antibody specificity is essential when introducing this reagent to new experimental systems. Researchers should implement a multi-faceted validation approach:

• Genetic validation:

  • Perform siRNA/shRNA knockdown of GK3P

  • Generate CRISPR/Cas9 knockout cell lines

  • Compare antibody signal between wildtype and genetic models

• Recombinant protein controls:

  • Test antibody against purified recombinant GK3P protein

  • Include closely related family members as negative controls

  • Perform peptide competition assays with immunizing peptide

• Orthogonal detection methods:

  • Compare antibody results with mRNA expression (qPCR, RNA-seq)

  • Utilize multiple antibodies targeting different GK3P epitopes

  • Employ mass spectrometry to confirm protein identity following immunoprecipitation

• Cross-species validation:

  • Verify conservation of the epitope sequence across target species

  • Test antibody in tissues with known expression patterns in multiple species

  • Confirm signal corresponds with expected physiological or pathological contexts

This comprehensive validation is particularly important for GK3P research due to its classification as a pseudogene product with potential sequence similarities to functional glycerol kinases . Documentation of these validation steps should be included in research publications to enhance reproducibility and reliability of findings.

How can researchers optimize GK3P antibody-based ELISA for quantitative analysis?

Optimizing GK3P antibody-based ELISA requires careful consideration of multiple parameters to ensure reliable quantitative results:

• Antibody pairing (for sandwich ELISA):

  • If using PACO13463 as capture antibody, pair with a detection antibody targeting a different epitope

  • Verify antibody compatibility through preliminary checkerboard titration

• Standard curve development:

  • Use recombinant GK3P protein at concentrations ranging from 0.1-1000 ng/mL

  • Prepare standards in the same matrix as samples (e.g., cell culture medium, serum-free)

  • Include at least 7-8 points for accurate curve fitting

• Sample preparation optimization:

  • Determine appropriate dilution factor through preliminary testing

  • Pre-clear complex samples via centrifugation (12,000g, 10 minutes)

  • For cell/tissue lysates, standardize protein concentration across samples

• Protocol refinement:

  • Optimize coating buffer composition (typically carbonate buffer pH 9.6)

  • Determine optimal coating concentration (usually 1-10 μg/mL)

  • Test various blocking agents (BSA, casein, commercial blockers)

  • Optimize incubation temperatures and times for each step

• Controls to include:

  • Background control (no primary antibody)

  • Matrix blank (sample diluent only)

  • Internal control samples with known GK3P concentrations

  • Spike recovery samples to assess matrix effects

This methodical approach enables researchers to develop a sensitive and specific ELISA for GK3P quantification . Regular calibration and inclusion of internal controls in each assay ensure reproducibility across experiments. When measuring GK3P in clinical samples, additional validation may be required to account for matrix effects specific to different biological fluids.

How does GK3P protein expression correlate with clinical outcomes in cancer patients?

The correlation between GK3P protein expression and clinical outcomes represents an emerging area of cancer research with important implications for prognosis and treatment selection. Based on current understanding of GK3P as a potential oncogene , researchers investigating these correlations should:

Since GK3P overexpression has been linked to various cancer types , researchers should carefully stratify patients according to cancer type and molecular subtype when analyzing correlations with clinical outcomes. Multivariate analysis incorporating established prognostic factors is essential for determining whether GK3P expression represents an independent prognostic biomarker.

What technical considerations are important when comparing results from different GK3P antibody clones?

When comparing results obtained using different GK3P antibody clones, researchers must address several technical considerations to ensure valid comparisons:

To facilitate direct comparisons, researchers should implement side-by-side testing of different antibody clones on identical sample sets . This approach allows for calibration of signals and establishment of conversion factors when necessary. Additionally, orthogonal validation (e.g., mass spectrometry, genetic models) provides greater confidence in findings that are consistent across multiple antibody clones. When publishing results, detailed reporting of antibody clone, catalog number, lot, and experimental conditions is essential for reproducibility.

How can researchers use GK3P antibodies to investigate protein-protein interactions?

Investigating GK3P protein-protein interactions requires strategic application of antibody-based techniques. Researchers should consider the following comprehensive approach:

• Co-immunoprecipitation (Co-IP):

  • Use GK3P antibody (PACO13463) for immunoprecipitation of protein complexes

  • Optimize lysis conditions to preserve native interactions

  • Consider crosslinking to stabilize transient interactions

  • Analyze precipitated complexes by:

    • Western blotting for suspected interaction partners

    • Mass spectrometry for unbiased interaction discovery

• Proximity ligation assay (PLA):

  • Pair GK3P antibody with antibodies against suspected interaction partners

  • Visualize interactions in situ with subcellular resolution

  • Quantify interaction signals across different experimental conditions

• Immunofluorescence co-localization:

  • Perform dual staining with GK3P and partner protein antibodies

  • Apply rigorous co-localization analysis using appropriate statistical methods

  • Confirm with super-resolution microscopy for precise spatial relationships

• Validation strategies:

  • Perform reciprocal Co-IP with partner protein antibodies

  • Use domain mutants to map interaction interfaces

  • Employ FRET or BRET assays for live-cell interaction monitoring

  • Validate physiologically relevant interactions through functional assays

This systematic approach allows researchers to build confidence in identified interactions through multiple, complementary techniques. When studying GK3P specifically, consideration should be given to its potential interactions with metabolic enzymes involved in glycerol metabolism and potentially with regulatory proteins that might influence its role in cancer development .

What are the emerging trends in GK3P antibody-based research methodologies?

The landscape of GK3P antibody-based research is evolving rapidly, with several emerging methodological trends enhancing both specificity and utility:

• Computational antibody design approaches:

  • Machine learning algorithms trained on phage display data now enable the prediction and design of antibodies with tailored specificity profiles

  • Biophysics-informed models can disentangle multiple binding modes, allowing for the generation of antibodies that discriminate between closely related ligands

  • These computational approaches expand beyond traditional selection methods, offering unprecedented control over antibody specificity

• Single-cell applications:

  • Adaptation of GK3P antibodies for mass cytometry (CyTOF) and imaging mass cytometry

  • Integration with single-cell RNA sequencing data for correlation of protein and mRNA at individual cell resolution

  • Development of highly multiplexed imaging techniques incorporating GK3P detection

• Advanced imaging modalities:

  • Implementation of super-resolution microscopy for precise subcellular localization

  • Expansion microscopy techniques for enhanced spatial resolution

  • Live-cell imaging with engineered antibody fragments for real-time monitoring

• Therapeutic and diagnostic translation:

  • Development of GK3P-targeting antibody-drug conjugates for cancer therapy

  • Exploration of GK3P antibodies in companion diagnostic applications

  • Incorporation into multiplexed diagnostic panels for cancer subtyping